Mao et al. [13] conjugated a human anti-Trop-2 Fab engineered antibody with doxorubicin (DOX) to form the complex of Trop-2 Fab-DOX to target Trop-2-expressing pancreatic cancer cells with a controlled release of DOX, and the results demonstrated the inhibitory effects on PC cell proliferation and migration with potent antitumor activity. Here, TACSTD2 is linked to pancreatic neoplasm.